What is carcinoma?
Carcinoma is the most common type of cancer. It begins in the epithelial tissue of the skin. Carcinoma can also start in the tissue of other organs, such as the liver or the pancreas. It may stay where it arose or spread to other organs, and it comes in several forms, including:
- Carcinoma in situ: an early-stage cancer confined to the tissue layer where it began. It has not spread to other organs of the body.
- Invasive carcinoma: cancer that has spread into the surrounding tissue.
- Metastatic carcinoma: cancer that has spread to other tissues and organs.
The most common carcinomas
Carcinomas can arise in many parts of the body. The most common types are:
Basal cell carcinoma (basalioma) — the most common skin cancer. The cancer cells develop in the basal layer of the skin. Basal cells usually grow more slowly, so the chance of metastasis and spread to other organs is low. The cure rate reaches up to 99%, and the chance of recurrence within 5 years is around 5%. Still, it can badly damage tissue locally (for example on the face) if left untreated.
Squamous cell carcinoma — the second most common skin cancer. The cancer cells develop in the squamous cells of the outer skin layer. Squamous cell cancer usually grows slowly, so the chance of metastasis is not high, but it is more inclined than basalioma to spread into the fatty layer beneath the skin. Survival is fairly high, up to 98%. The recurrence rate is 6.7%, and 96% of recurrences happen within 2 years of treatment. The risk rises if the tumor appears on the lips, ears, or in people with immunodeficiency — then it is more aggressive.
Clear cell carcinoma — the most common type of kidney cancer. The cancer arises in the cells of the kidney tubule. The overall 5-year survival for kidney carcinoma is 75%. After the tumor is removed (nephrectomy), the chance the cancer returns is 20% to 40%. Clear cell carcinoma is treacherous because it can “sleep” and return many years later, so monitoring after nephrectomy is critical. It is also very important to look after the factors and lifestyle habits you can influence, to reduce the chance of recurrence as much as possible.
Ductal carcinoma in situ (DCIS) — the most common type of breast cancer. The cancer cells are confined to the walls of the milk ducts and have not spread into the surrounding breast tissue. The 5-year survival for DCIS (Stage 0) is 99%. The chance of recurrence within 15 years is 20–30% if a woman declines additional treatment (radiotherapy or hormone therapy) after surgery. With full treatment, this risk falls to 10–15%.
Invasive ductal carcinoma — the cells have mutated in the milk ducts and broken through into the surrounding tissue. From there the cancer can spread to other parts of the body. If you are diagnosed with invasive ductal carcinoma, the overall 10-year survival is 84%. It depends heavily on spread (with no metastases, survival is 99%); if the cancer has spread to a distant part of the body, the 5-year survival is 30–31%.
Carcinoma treatment
Treatment of carcinoma differs by type, location, size and spread, but may include:
Surgery: depending on the cancer type, carcinoma can be treated surgically by removing the cancerous and surrounding tissue. Minimally invasive surgery can shorten recovery time and reduce the risk of infection after the operation.
Radiotherapy: may be used together with surgery and/or chemotherapy. Advanced techniques let oncologists carefully track the tumor during and after treatment. Radiotherapy may use X-rays, gamma rays and others; radioactive substances may also be given or injected into a vein. Radiotherapy raises the chance of developing cancer again. Its side effects depend heavily on the dose and are divided into those appearing soon and those appearing later, from a few months to a few years. The most common immediate effect is weakness; other symptoms depend on the specific cancer type. In any case, the side effects of radiotherapy are smaller than those of chemotherapy.
Chemotherapy: one of the most common cancer treatments. These are anti-cancer drugs that target rapidly dividing cells throughout the body or in a specific area.
What I can do in the fight against carcinoma
Alcohol is toxic to cells, so drinking it can speed up damage and bring avoidable consequences. It is best to give up alcohol.
Mushrooms have been used as medicine for thousands of years for their unmatched pharmacological range. Lentinan, from the Lentinus edodes medicinal mushroom, is the most thoroughly studied and documented anti-cancer compound, best known for stimulating immunity (activating cytokines, macrophages, NK and other immune cells).
Frequently Asked Questions
A tumor is an abnormal growth of cells in the body. Tumors can be benign (not dangerous) or malignant (cancerous). Malignant tumors can spread to other organs — this is called metastasis.
Yes. The immune system is the main defense against altered cells. Mushroom polysaccharides are studied for their role in activating NK cells and macrophages, which recognize and act on tumor cells. It is important to choose a concentrated multi-extract formula such as Lentinan AXT by Zenius Labs™.
A benign tumor grows slowly, does not spread to other organs, and is usually not life-threatening. A malignant tumor (cancer) grows faster, can invade surrounding tissue, and can metastasise — spreading through the blood or lymph to distant parts of the body.
Symptoms depend on the location and type. Common signs are an unexplained lump, unexplained weight loss, persistent fatigue, pain, and unusual bleeding. Regular preventive check-ups help diagnose tumors early.
Treatment depends on type, stage and location. The most common methods are surgery, chemotherapy, radiotherapy and immunotherapy. Immune-system support during and after treatment is very important for recovery.
- Antitumor polysaccharides from mushrooms: structural characteristics, antitumor mechanisms and immunomodulating activities. PubMed
- Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Jia XM et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. The Journal of experimental medicine. 2014. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Zhou G et al. Lentinan progress in inflammatory diseases and tumor diseases. European journal of medical research. 2024. PubMed
- Deng S et al. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR. 2018. PubMed
- You J et al. Lentinan induces apoptosis of mouse hepatocellular carcinoma cells through the EGR1/PTEN/AKT signaling axis. Oncology reports. 2023. PubMed
- Amino M et al. [Studies on the effect of lentinan on human immune system. II. In vivo effect on NK activity, MLR induced killer activity and PHA induced blastic response of lymphocytes in cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy. 1983. PubMed
- Zhen C et al. Comprehensive mechanisms and advanced delivery strategies of lentinan in antitumor therapy: A review. Colloids and surfaces. B, Biointerfaces. 2026. PubMed
- Chihara G Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Developments in biological standardization. 1992. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology. 2013. PubMed
- Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer research. 2012. PubMed
- Chang Y et al. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discovery medicine. 2017. PubMed
- Standish LJ et al. Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology. 2008. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed
- Copat C et al. Astaxanthin in cancer therapy and prevention (Review). Biomedical reports. 2025. PubMed
- Li J et al. Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro. Marine drugs. 2015. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
- Saini RK et al. Dietary carotenoids in cancer chemoprevention and chemotherapy: A review of emerging evidence. Pharmacological research. 2020. PubMed
- Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
- Dan A et al. Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review. Cureus. 2023. PubMed